COVID-19 vaccines induce robust cellular immunity against Omicron variant
A new study by researchers at Beth Israel Deaconess Medical Center (BIDMC) demonstrated that cellular immunity — or the production of protective immune cells, such as so-called killer and memory cells — induced by current COVID-19 vaccines, provided robust protection against severe disease caused by both the Delta and Omicron variants.
The team assessed samples from 47 individuals vaccinated with either the Johnson & Johnson or Pfizer-BioNTech vaccines. The findings are published in Nature.
“Our data provide immunological context for the observation that current vaccines still provide robust protection against severe disease and hospitalization, due to the Omicron variant, despite substantially reduced neutralizing antibody responses and increased breakthrough infection,” said corresponding author Dan H. Barouch, MD, PhD, Director of the Center for Virology and Vaccine Research at BIDMC, whose team was involved in the development of the Johnson & Johnson vaccine.
Using samples from uninfected individuals who received either the Johnson & Johnson or Pfizer-BioNTech vaccines, Barouch and colleagues measured CD8+ T cell and CD4+ T cell responses to the original, Delta, and Omicron strains of the SARS-CoV-2 virus after one month and then again after eight months following final vaccination. They likewise assessed antibody responses to the variants at one and eight months out.
Consistent with previous reports, the scientists observed minimal cross-reactive Omicron-specific neutralizing antibodies. In contrast, the team’s data suggested that Omicron-specific CD8+ T cell responses were more than 80% cross-reactive with the CD8+ T cell response to the original strain of the virus. Similarly, more than 80% of Omicron-specific CD4+ T cells demonstrated cross-reactivity, although responses could vary among individuals, the scientists note.
“Given the role of CD8+ T cells in clearance of viral infections, it is likely that cellular immunity contributes substantially to vaccine protection against severe SARS-CoV-2 disease,” said Barouch, Professor of Medicine at Harvard Medical School and a member of the Ragon Institute of MGH, MIT, and Harvard. “This may be particularly relevant for Omicron, which dramatically evades neutralizing antibody responses.”
